Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain

• F. Couñago ^[1] ; G. Sancho ^[2] ; A. Gómez-Iturriaga ^[3] ; I. Henríquez ^[4] ; SEOR
  1. [1] Hospital Universitario Quirónsalud Madrid

     Hospital Universitario Quirónsalud Madrid

     Madrid, España

     
  2. [2] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  3. [3] Instituto de Investigación Sanitaria Biobizkaia

     Instituto de Investigación Sanitaria Biobizkaia

     Barakaldo, España

     
  4. [4] Hospital Universitario de Sant Joan, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 11 (November 2018), 2018, págs. 1484-1491
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To investigate patterns of practice among Spanish radiation oncologists in the use of multiparametric magnetic resonance imaging (mpMRI) for the treatment of prostate cancer (PCa). We evaluated (1) access to mpMRI, (2) current clinical practices, and (3) physician expectations of mpMRI.

    Methods Cross-sectional survey of 118 radiation oncologists at 75 Radiation Oncology (RO) departments in Spain.

    Results A total of 55 radiation oncologists from 52 RO departments (52/75; 69%) completed the survey. Prostate mpMRI is performed at 94.5% of the centres that provided data. The most common indications for mpMRI in routine clinical practice were: (1) detection/localization of the tumour prior to second biopsy (82.7%), (2) cancer staging (80.8%), and (3) detection of recurrence after definitive treatment (80.8%). Most respondents (72.7%) reported modifying the primary radiotherapy treatment when mpMRI findings indicate a more advanced T stage with a resultant change in the risk group. Most respondents (90.5%) treat macroscopic local recurrence after prostatectomy with high doses, ranging from 71 to 83 Gy; in 37.7% of cases, the full dose is delivered to the entire prostate bed. In pelvic nodal recurrence, more than half (59.3%) of the respondents reported performing elective pelvic radiotherapy, including the prostate bed, with a boost to the involved nodes.

    Conclusions This survey shows that prostate mpMRI is routinely used by radiation oncologists in Spain in a wide range of clinical scenarios. The findings reported here underscore the need to standardize treatment protocols for definitive and salvage radiotherapy in patients evaluated with mpMRI.